Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
Recruiting · NCT07288489 · Registry updated 2026-08-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin. | Blood Loss, Surgical, Hemic and Lymphatic Diseases, Hemorrhage, Intraoperative Complications, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blood coagulation disease, cardiovascular disorder, hematologic disorder, hemorrhagic disease, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-08-21 | NCT07288489 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| VarmX B.V. | 1 |
37 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.